Appendix cancer other diagnostic studies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
:* [[Enteroscopy]] | :* [[Enteroscopy]] | ||
:* [[Positron emission tomography]] (PET) | :* [[Positron emission tomography]] (PET) | ||
* The following are among biochemocal markers that might represent level of [[malignant]] cells activity in [[carcinoid syndrome]] | * The following are among biochemocal markers that might represent level of [[malignant]] cells activity in [[carcinoid syndrome]]: | ||
:* [[Chromogranin A]] ([[Chromogranin A|CgA]])<ref name="pmid10940685">Eriksson B, Oberg K, Stridsberg M (2000) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10940685 Tumor markers in neuroendocrine tumors.] ''Digestion'' 62 Suppl 1 ():33-8. [http://dx.doi.org/10.1159/000051853 DOI:10.1159/000051853] PMID: [https://pubmed.gov/10940685 10940685]</ref> | :* [[Chromogranin A]] ([[Chromogranin A|CgA]])<ref name="pmid10940685">Eriksson B, Oberg K, Stridsberg M (2000) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10940685 Tumor markers in neuroendocrine tumors.] ''Digestion'' 62 Suppl 1 ():33-8. [http://dx.doi.org/10.1159/000051853 DOI:10.1159/000051853] PMID: [https://pubmed.gov/10940685 10940685]</ref> | ||
:* [[5-Hydroxyindoleacetic acid|5-HIAA]] ([[5-Hydroxyindoleacetic acid|5-hydroxyindoleacetic acid]])<ref name="pmid10604122">Oberg K, Janson ET, Eriksson B (1999) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10604122 Tumour markers in neuroendocrine tumours.] ''Ital J Gastroenterol Hepatol'' 31 Suppl 2 ():S160-2. PMID: [https://pubmed.gov/10604122 10604122]</ref> | :* [[5-Hydroxyindoleacetic acid|5-HIAA]] ([[5-Hydroxyindoleacetic acid|5-hydroxyindoleacetic acid]])<ref name="pmid10604122">Oberg K, Janson ET, Eriksson B (1999) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10604122 Tumour markers in neuroendocrine tumours.] ''Ital J Gastroenterol Hepatol'' 31 Suppl 2 ():S160-2. PMID: [https://pubmed.gov/10604122 10604122]</ref> | ||
:* Ki67: a reliable marker of [[Cell growth|cell proliferation]] <ref name="pmid14686708">Oberg K (2003) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=14686708 Diagnosis and treatment of carcinoid tumors.] ''Expert Rev Anticancer Ther'' 3 (6):863-77. [http://dx.doi.org/10.1586/14737140.3.6.863 DOI:10.1586/14737140.3.6.863] PMID: [https://pubmed.gov/14686708 14686708]</ref><ref name="pmid17576444">Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C et al. (2006) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=17576444 Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.] ''Curr Oncol'' 13 (2):67-76. PMID: [https://pubmed.gov/17576444 17576444]</ref> | :* Ki67: a reliable marker of [[Cell growth|cell proliferation]]<ref name="pmid14686708">Oberg K (2003) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=14686708 Diagnosis and treatment of carcinoid tumors.] ''Expert Rev Anticancer Ther'' 3 (6):863-77. [http://dx.doi.org/10.1586/14737140.3.6.863 DOI:10.1586/14737140.3.6.863] PMID: [https://pubmed.gov/14686708 14686708]</ref><ref name="pmid17576444">Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C et al. (2006) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=17576444 Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.] ''Curr Oncol'' 13 (2):67-76. PMID: [https://pubmed.gov/17576444 17576444]</ref> | ||
Revision as of 16:33, 20 February 2019
|
Appendix cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Appendix cancer other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Appendix cancer other diagnostic studies |
|
Risk calculators and risk factors for Appendix cancer other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Appendix cancer may also be diagnosed using scintigraphy, capsule endoscopy, enteroscopy, positron emission tomography (PET). Chromogranin A (CgA) and 5-HIAA (5-hydroxyindoleacetic acid) are among biochemical markers that might represent level of malignant cells activity in carcinoid syndrome.
Other Diagnostic Studies
- Somatostatin scintigraphy with 111-indium-octreotide
- Bone scintigraphy with 99mTc-methylene diphosphonate (99mTcMDP)
- Capsule endoscopy
- Enteroscopy
- Positron emission tomography (PET)
- The following are among biochemocal markers that might represent level of malignant cells activity in carcinoid syndrome:
- Chromogranin A (CgA)[2]
- 5-HIAA (5-hydroxyindoleacetic acid)[3]
- Ki67: a reliable marker of cell proliferation[4][1]
References
- ↑ 1.0 1.1 Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C et al. (2006) Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol 13 (2):67-76. PMID: 17576444
- ↑ Eriksson B, Oberg K, Stridsberg M (2000) Tumor markers in neuroendocrine tumors. Digestion 62 Suppl 1 ():33-8. DOI:10.1159/000051853 PMID: 10940685
- ↑ Oberg K, Janson ET, Eriksson B (1999) Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol 31 Suppl 2 ():S160-2. PMID: 10604122
- ↑ Oberg K (2003) Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 3 (6):863-77. DOI:10.1586/14737140.3.6.863 PMID: 14686708